

NEWS RELEASE



March 11, 2022

The result of an Investigator-Initiated Clinical Trial (First In Human trial) of NS-089/NCNP-02 for the treatment of Duchenne muscular dystrophy

Kyoto, Japan, March 11, 2022 - Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; Headquarters, Kyoto; President, Toru Nakai) announced today that the National Center of Neurology and Psychiatry (NCNP, Kodaira City; President, Kazuyuki Nakagome) will present about the result of an Investigator-Initiated Clinical Trial (First In Human trial) of NS-089/NCNP-02 for the treatment of Duchenne muscular dystrophy at the Muscular Dystrophy Association conference from March 13th to 16th.

The poster presentation will be available for viewing from 6pm CST on March 13th, and virtual presentation will be available for viewing on March 16th. To access to the presentation, you will need to register on the website of the Muscular Dystrophy Association. For more information, please visit the website below.

<https://mdaconference.org>

NS-089/NCNP-02 is an antisense oligonucleotide co-discovered by NCNP and Nippon Shinyaku, and is expected to be a therapeutic drug for Duchenne muscular dystrophy patients who have dystrophin gene mutations that are amenable to exon 44 skipping.

Contact

Corporate Communications Dept., Nippon Shinyaku

FAX: +81-75-321-9128